Heart Transplant clinical trials at UCSF
4 in progress, 3 open to eligible people
A heart transplant replaces a damaged heart with a healthy one. UCSF is conducting trials to find ways to aid recovery after this operation. One trial adds Levothyroxine supplements for transplant recipients. Another study assesses cardiac rehabilitation, comparing the effectiveness of in-person and telehealth approaches.
Levothyroxine Supplementation for Heart Transplant Recipients
open to eligible people ages 18 years and up
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
San Francisco, California
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
open to eligible people ages 18 years and up
Cardiac rehabilitation is a medically recommended program for patients with certain heart conditions. It includes exercise training, health education, and counseling. Unfortunately, many patients do not participate in cardiac rehabilitation. Some find it challenging to attend the in-person sessions. This study aims to compare two methods of delivering cardiac rehabilitation: in-person and through telehealth. The investigators want to know if the effects of these two programs are alike and if certain individuals benefit more from one program over the other.
San Francisco, California and other locations
US National OCS Heart Perfusion (OHP) Registry
open to all eligible people
This Registry is a sponsor initiated, multi-center, observational post-approval registry with independent academic oversight.
San Francisco, California and other locations
Surveillance HeartCare® Outcomes Registry
Sorry, in progress, not accepting new patients
This is an observational registry to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.
San Francisco, California and other locations
Our lead scientists for Heart Transplant research studies include Liviu Klein, MD Alexis Beatty, MD, MAS.
Last updated: